Balanced CDK4/6 inhibition & dosing schedule: 21 days on, 7 days off
For a significant advancement in the treatment of HR-positive, HER2-negative breast cancer, you need to fortify the combination therapy models.
You will be a key player and standard-bearer in the oncology, if you include Nanomedicine mode of actions in your combination therapy strategies.
#Ibrance (#Palbociclib):
#Manufacturer: Pfizer Inc.
#Mechanism of Action: Ibrance works by selectively inhibiting CDK4 and CDK6, thereby preventing the phosphorylation of the retinoblastoma (Rb) protein, which is a crucial step for cell cycle progression from the G1 to the S phase. This action results in cell cycle arrest and inhibits cancer cell growth.
#Impact: Significantly improve progression-free survival (PFS) in patients with advanced or metastatic breast cancer. Patients treated with Ibrance in combination with endocrine therapy had a longer PFS compared to those treated with endocrine therapy alone.
#Sales: Ibrance has achieved blockbuster status with annual sales exceeding $5 billion.
Reasons for Blockbuster Status:
1. #Efficacy: Clinical trials (e.g., PALOMA-1, PALOMA-2, PALOMA-3) have shown substantial improvements in progression-free survival.
2. #CombinationTherapy: Ibrance is effective in combination with standard endocrine therapies, enhancing its appeal and applicability.
3. #BroadApplicability: It addresses a significant subset of breast cancer patients, particularly those who are HR-positive and HER2-negative.
4. #SafetyProfile: Ibrance is generally well-tolerated, with manageable side effects, making it a preferable option for long-term treatment.
5. #MarketStrategy: Pfizer's robust marketing and strategic partnerships have facilitated widespread adoption and physician confidence in prescribing Ibrance.
Summary of #CombinationTherapies:
Ibrance + Letrozole: Often used as a first-line therapy for postmenopausal women with HR+/HER2- advanced breast cancer.
Ibrance + Anastrozole or Exemestane: Alternative aromatase inhibitors used with Ibrance.
Ibrance + Fulvestrant: Used for patients with disease progression following endocrine therapy.
Ibrance + Goserelin: For premenopausal women to achieve ovarian suppression.
#SideEffects
Neutropenia, Fatigue, Nausea, Hair Thinning or Hair Loss, Diarrhea, Stomatitis, Anemia, Thrombocytopenia, Infections, Decreased Appetite, etc.
Severe Side Effects: Severe Infections, Pulmonary Embolism, Febrile Neutropenia, Severe Anemia, Interstitial Lung Disease/Pneumonitis.
